

*b2*

6. (Amended) A method according to claim 1 wherein the epithelial cell sample from the patient is a lung cell sample or a nasal cell sample.

*b3*

12. (Amended) A method according to claim 7 wherein the epithelial cell sample from the patient is a lung cell sample or a nasal cell sample.

*b3*

13. (Amended) A method according to claim 7 wherein the effectiveness of a treatment for cystic fibrosis is being tested on the patient.

*b3*

20. (Amended) A method according to claim 14 wherein the method is carried out *in vivo*.

*b3*

23. (Amended) A compound identified by the method of claim 14.

*b3*

32. (Amended) A peptide according to claim 31 which comprises SEQ. ID. NO. 1.

*b3*

33. (Amended) A peptide according to claim 28 further comprising a lipid-solubilising moiety.

*b3*

36. (Amended) A peptide according to claim 33 wherein the lipid-solubilising moiety is a fatty acid.

*b3*

39. (Amended) A pharmaceutical formulation comprising a peptide according to claim 28 and a pharmaceutically acceptable carrier.

*b3*

40. (Amended) A method of treating cystic fibrosis or a chronic sputum producing disorder, the method comprising administering to a patient an effective amount of a peptide according to claim 28.

b9  
45. (Amended) A peptide according to claim 43 wherein the histidine residue is phosphorylated.

b1b  
48. (Amended) An antibody obtainable by the method of claim 46.

Pursuant to 37 CFR §1.121(c)(1)(iii), a marked up version of these claims accompanies this amendment.

51. (New) A method according to claim 4 wherein the epithelial cell sample from the patient is a lung cell sample or a nasal cell sample.

B1N  
52. (New) A method according to claim 17 wherein the method is carried out *in vivo*.

53. (New) A method according to claim 19 wherein the method is carried out *in vivo*.

53. (New) A compound identified by the method of claim 17.

54. (New) A compound identified by the method of claim 19.

55. (New) A compound identified by the method of claim 21.

56. (New) A peptide according to claim 44 wherein the histidine residue is phosphorylated.

57. (New) An antibody obtainable by the method of claim 47.